非肝素抗凝药治疗肝素诱导性血小板减少症的比较有效性与安全性
该系统评价与Meta分析检索EMBASE和Medline,纳入92项研究、119个治疗组、4698例急性HIT患者,评估非肝素抗凝药的血小板恢复、血栓栓塞、大出血和死亡发生率。结果显示各药物有效性及安全性结局相似,置信区间多重叠,未发现显著影响因素,支持磺达肝癸钠和直接口服抗凝药作为常规抗凝药的可行替代。
要点
- 磺达肝癸钠血小板恢复率99%、血栓栓塞1%、死亡7%,表现较好。
- 直接口服抗凝药大出血率1%,为各药中最低。
- 比伐芦定血小板恢复率74%、大出血14%、死亡19%,相对较差。
核心结论
- 不同非肝素抗凝药治疗急性HIT的有效性和安全性结局相似。
- 未发现显著影响结局的因素。
- 研究结果支持磺达肝癸钠和直接口服抗凝药作为急性HIT的可行替代治疗。
研究设计与样本
- 系统评价与Meta分析,遵循PROSPERO方案CRD42020219027。
- 检索EMBASE和Medline,纳入92项研究、119个治疗组、4698例急性HIT患者。
- 采用随机效应模型合并各药物结局比例,并评估患者人群、诊断试验、研究设计及文章类型的影响。
主要发现
- 血小板恢复率从比伐芦定74%至磺达肝癸钠99%。
- 血栓栓塞率从磺达肝癸钠1%至达那肝素7%。
- 大出血率从直接口服抗凝药1%至比伐芦定14%。
- 死亡率从磺达肝癸钠7%至比伐芦定19%。
- 各药结局置信区间多重叠,且未受患者人群、诊断试验、研究设计或文章类型影响。
关键数值与推荐
- 磺达肝癸钠:血小板恢复99%,血栓栓塞1%,死亡7%。
- 直接口服抗凝药:大出血1%。
- 比伐芦定:血小板恢复74%,大出血14%,死亡19%。
- 达那肝素:血栓栓塞7%。
临床怎么用
- 临床可考虑将磺达肝癸钠和直接口服抗凝药作为急性HIT的替代抗凝选择。
- 选择药物时需综合评估各药有效性及安全性数据,注意比伐芦定大出血和死亡风险相对较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effectiveness and safety of non-heparin anticoagulants for the treatment of heparin-induced thrombocytopenia (HIT) are not fully established, and the optimal treatment strategy is unknown. In a systematic review and meta-analysis, we aimed to determine precise rates of platelet recovery, new or progressive thromboembolism (TE), major bleeding, and death for all non-heparin anticoagulants and to study potential sources of variability. METHODS: Following a detailed protocol (PROSPERO: CRD42020219027), EMBASE and Medline were searched for all studies reporting clinical outcomes of patients treated with non-heparin anticoagulants (argatroban, danaparoid, fondaparinux, direct oral anticoagulants [DOAC], bivalirudin, and other hirudins) for acute HIT. Proportions of patients with the outcomes of interest were pooled using a random-effects model for each drug. The influence of the patient population, the diagnostic test used, the study design, and the type of article was assessed. RESULTS: Out of 3194 articles screened, 92 studies with 119 treatment groups describing 4698 patients were included. The pooled rates of platelet recovery ranged from 74% (bivalirudin) to 99% (fondaparinux), TE from 1% (fondaparinux) to 7% (danaparoid), major bleeding from 1% (DOAC) to 14% (bivalirudin), and death from 7% (fondaparinux) to 19% (bivalirudin). Confidence intervals were mostly overlapping, and results were not influenced by patient population, diagnostic test used, study design, or type of article. DISCUSSION: Effectiveness and safety outcomes were similar among various anticoagulants, and significant factors affecting these outcomes were not identified. These findings support fondaparinux and DOACs as viable alternatives to conventional anticoagulants for treatment of acute HIT in clinical practice.
引用
- Nilius H, Kaufmann J, Cuker A, et al. Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia. Am J Hematol. 2021. PMID: 33857342. doi:10.1002/ajh.26194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。